Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phylebotomy-induced anemia and bone marrow ablation

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 4, 2004, Pages 149-156

  Veng Pedersen, P ^a   Chapel, S ^a,c   Al Huniti, N H ^a   Schimdt, R L ^b   Sedars, E M ^b   Hohl, R J ^b   Widness, J A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c SANOFI   (France)

Author keywords

Busulfan ablation; Drug tracer; Erythropoietin receptor; Phlebotomy; Receptor regualtion

Indexed keywords

AMPICILLIN; BUSULFAN; CELL SURFACE RECEPTOR; ERYTHROPOIETIN RECEPTOR; IODINE 125; RECOMBINANT ERYTHROPOIETIN; TRACER;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; ERYTHROID PRECURSOR CELL; IN VIVO STUDY; ISOTOPE LABELING; LINEAR SYSTEM; NONHUMAN; PHLEBOTOMY; RECEPTOR UPREGULATION; SHEEP;

ALKYLATING AGENTS; ANEMIA; ANIMALS; BONE MARROW; BUSULFAN; CATHETER ABLATION; ERYTHROPOIETIN, RECOMBINANT; HALF-LIFE; METABOLIC CLEARANCE RATE; PHLEBOTOMY; RECEPTORS, ERYTHROPOIETIN; SHEEP;

EID: 2942670041     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.395     Document Type: Article

References (37)

1. Fisher JW. Erythropoietin: physiology and pharmacology Update. Exp Biol Med 2003; 228: 1-14.
2. Sawyer ST. Receptors for erythropoietin. In Distribution, Structure, and Role in Receptor-mediated Endocytosis in Erythroid Cells. Plenum: New York, 1990; 365-402.
3. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Develop 1998; 52: 235-249.
4. Juul SE, Ledbetter DJ, Joyce AE, et al. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001; 49: 182-189.
5. Veng-Pedersen P, Widness JA, Wang J, Schmidt RL. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J Pharmacokinet Biopharm 1997; 25: 569-593.
6. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001; 29: 425-431.
7. Chapel SH, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widnes JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001; 298: 820-827.
8. Widness JA, Schmidt RL, Veng-Pedersen P, Modi N, Sawyer ST. A sensitive and specific erythropoietin immunoprecipitation assay: Application to pharmacokinetic studies. J Lab Clin Med 1992; 119: 285-294.
9. Widness JA, Garcia JF, Clemons GK, et al. Temporal response of immunoreactive erythropoietin to acute hypoxemia in the sheep fetus. Pediatr Res 1986; 20: 15-19.
10. Clapp DW, Dumenco LL, Hatzoglou M, Gerson SL. Fetal liver hematopoietic stem cells as a target for in utero retroviral gene transfer. Blood 1991; 78: 1132-1139.
11. Clapp DW, Freie B, Lee WH, Zhang YY. Molecular evidence that in situ-transduced fetal liver hematopoietic stem/progenitor cells give rise to medullary hematopoiesis in adult rats. Blood 1995; 86: 2113-2122.
12. Veng-Pedersen P. Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 1977; 5: 513-531.
13. Veng-Pedersen P. Linear and nonlinear system approaches in pharmacokinetics. How much do they have to offer? J Pharmacokin Biopharm 1988; 16: 413-472.
14. Hutchinson MF, deHoog FR. Smoothing noise data with spline functions. Numer Math 1985; 47: 99-106.
15. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997; 96: 227-240.
16. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996; 279: 1205-1210.
17. Kendall RG, Chapman C, Hartley AE, Norfolk DR. Storage and preparation of samples for erythropoietin radioimmunoassay. Clin Lab Haematol 1991; 13: 189-196.
18. Eckhardt KU, Chapman C, Hartley AE, Norfolk DR. Storage and preparation of samples for erythropoietin radioimmunoassay. Clin Lab Haematol 1991; 13: 189-196.
19. Mufson RA, Gesner TG. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 1987; 69: 1485-1490.
20. Sawyer ST, Hankins WD. The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation. Proc Natl Acad Sci USA 1993; 90: 6849-6853.
21. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 1987, 262: 5554-5562.
22. Gammeltoft S. Receptor-Mediated Endocytosis and Degradation of Polypeptide Hormones, Growth Factors, and Neuropeptides. CRC Press: Boston; 123-140.
23. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91: 2139-2145.
24. Stohlman F. Observations on the physiology of erythropoietin and its role in the regulation of red cell production. Ann N Y Acad Sci 1959; 77: 710-724.
25. Jelkmann W, Wiedamann. Serum Ep level: Relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow. Klin Wochenschr 1990; 68: 403-407.
26. Grace RJ, Kendall RG, Chapman C, Hartley AE, Barnard DL, Norfolk DR. Changes in serum erythropoietin levels during allogeneic bone marrow transplantation. Eur J Haematol 1991; 47: 81-85.
27. Davies SV, Fegan CD, Kendall R, Beguin Y Cavill I. Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity. Clin Lab Haematol 1995; 17: 139-144.
28. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283: 520-527.
29. Kato M, Miura K, Kamiyama H, et al. Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metabol Dispos 1998; 26: 126-131.
30. Flaharty KK. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO). Pharmacotherapy 1990; 10: 9S-14S.
31. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999; 20: 217-223.
32. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-767.
33. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47: 557-564.
34. Yasada Y NM, Okano M, Masuda S, et al. Localization of erythropoietin and erythropoietin-receptor in postimplantation mouse embryos. Dev Growth Differ 1993; 35: 711-722.
35. Carlini RG, Alonzo EJ, Dominguez J, et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999; 55: 546-553.
36. Yamaji R, Okada T, Moriya M, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500.
37. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002; 438: 36-42.